Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA)

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 6, 1998, Pages 599-604

  Trusen, Burkhard ^a   Ries, Martin ^a   Zenker, Martin ^a   Rauh, Manfred ^a   Beinder, Ernst ^a   Keuper, Hermann ^b   Harms, Dieter ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Behringwerke AG   (Germany)

Author keywords

Fibrinolysis; Newborn; Recombinant tissue plasminogen activator; Whole blood clot lysis

Indexed keywords

ALTEPLASE;

BLOOD CLOT LYSIS; BLOOD SAMPLING; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032457438     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996060     Document Type: Review

References (49)

1. 1. Ambrus CM, Ambrus JL, Choi S, et al. The fibrinolysin system and its relationship to disease in the newborn. Am J Pediatr Hematol Oncol 1979;1:251-260
2. 2. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full term infant. Blood 1987;70:165-172
3. 3. Corrigan JJ. Neonatal thrombosis and the thrombolytic system: Pathophysiology and therapy. Am J Pediatr Hematol Oncol 1988;10:83-89
4. 4. Corrigan JJ, Sleeth JJ, Jeter MA, Lox CD. Newborn's fibrinolytic mechanism: Components and plasmin generation. Am J Hematol 1989;32:273-278
5. 5. Ekelund H, Hedner U, Nilsson IM. Fibrinolysis in newborns. Acta Paediatr Scand 1970;59:33-43
6. 6. Estelles A, Aznar J, Gilabert J, Parrilla JJ. Dysfunctional plasminogen in full-term newborn. Pediatr Res 1980;14:1180-1185
7. 7. Benavent A, Estellés A, Aznar J, et al. Dysfunctional plasminogen in full term newborn - Study of active site of plasmin. Thromb Haemost 1984;51:67-70
8. 8. Edelberg JM, Enghild JJ, Pizzo SV, Gonzales-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990;86:106-112
9. 9. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104
10. 10. Saleh AA, Hirokawa S, Stowers MA, et al. Effect of mode of delivery on certain parameters of neonatal hemostasis. Thromb Haemost 1993;69:1020. Abstract
11. 11. Suarez CR, Walenga J, Mangogna LC, Fareed J. Neonatal and maternal fibrinolysis: Activation at time of birth. Am J Hematol 1985;19:365-372
12. 12. Ries M, Zenker M, Klinge J, Keuper H, Harms D. Age related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. Am J Pediatr Hematol Oncol 1995;17:260-264
13. 13. Andrew M, Brooker L, Leaker M, Paes B, Weitz J. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 1992;68: 325-330
14. 14. Ries M, Klinge J, Rauch R, Trusen B, et al. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in new borns and adults. Am J Pediatr Hematol Oncol 1996;18:346-351
15. 15. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237-246
16. 16. Beer JH, Kläy HP, Herren T, Haeberli A, Straub PW. Whole blood clot lysis: Enhanced by exposure to autologous but not to homologous plasma. Thromb Haemost 1994;71:622-626
17. 17. Rijken DC, Scifried E, Barret-Bergshoeff MM, Dooijewaard G. Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue type plasminogen activator or other thrombolytic agents. Thromb Haemost 1980;64:47-52
18. 18. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-1657
19. 19. Barnard DR, Simmons MA, Hathaway WE. Coagulation studies in extremely premature infants. Pediatr Res 1979;13:133-135
20. 20. Forestier F, Daffos F, Galactéros F, et al. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986;20:342-346
21. 21. Holmberg L, Henriksson P, Ekelund H, Âsted B. Coagulation in the human fetus, comparison with term newborn infants. J Pediatr 1974;85:860-864
22. 22. Jensen AH, Josso F, Zamet P, Monset-Couchard M, Minkowski A. Evolution of blood clotting factor levels in premature infants during the first 10 days of life: A study of 96 cases with comparison between clinical status and blood clotting factor levels. Pediatr Res 1973;7:638-644
23. 23. Künzer W. Fetales Fibrinogen. Klin Wochenschr 1961;39:536-542
24. 24. Witt I, Müller H, Künzer W. Evidence for the existence of foetal fibrinogen. Thrombosis et Diathesis Haemorrhagica 1969;22: 101-109
25. 25. Schettini F, De Mattia D, Mautone A. Preprothrombin and prothrombin in full term newborns. Haemostasis 1972;1:271-278
26. 26. Ekelund H. Fibrinolysis in the first year of life. Acta Paediatr Scand 1972;61:5-10
27. 27. Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989;62: 1083-1087
28. 28. Sakata Y, Aoki N. Significance of cross-linking of a2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982;69:536-542
29. 29. Kunitada S, Fitzgerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992;79:1420-1427
30. 30. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of a2-antiplasmin to fibrin. Thromb Haemost 1992;68:315-320
31. 31. Van Giezen JJJ, Chung-A-Hing JE, Vegter CB, Bouma BN, Jansen JWC. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. Thromb Haemost 1994;72:887-892
32. 32. Morez LA. Non-plasmin mediated fibrinolysis. Semin Thromb Hemost 1984;10:80-86
33. 33. Van Gelder JM, Nair CH, Dhall DP. Erythrocyte aggregation and erythrocyte deformability modify the permeability of erythrocyte enriched fibrin network. Thromb Res 1996;82:33-42
34. 34. Wu JH, Diamond SL. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. J Clin Invest 1995;95:2483-2490
35. 35. Sobel BE, Nachowiak DW, Fry ET, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to "plasminogen steal" and its implications for coronary thrombolysis. Coron Artery Dis 1990;1:111-119
36. 36. Torr SR, Nachowiak DA, Fujii S, Sobel BE. "Plasminogen steal" and clot lysis. J Am Coll Cardiol 1992;19:1085-1090
37. 37. Nishino N, Kakkar VV, Scully MF. Influence of intrinsic and extrinsic plasminogen upon lysis of thrombi in vitro. Thromb Haemost 1991;66:672-677
38. 38. Onundarson PT, Francis CW, Marder VJ. Depletion of plasminogen in vitro during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1992;120:120-128
39. 39. Ahluwalia JS, Kelsall AWR, Diederich S, Rennie JM. Successful treatment of aortic thrombosis after umbilical catheterisation with tissue plasminogen activator. Acta Paediatr 1994;83: 1215-1217
40. 40. Ries M, Singer H, Hofbeck M. Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect. Br Heart J 1994;72:201-202
41. 41. Van Overmeire B, Van Reempts PJ, Van Acker KJ. Intracardiac thrombus formation with rapidly progressive heart failure in the neonate: Treatment with tissue plasminogen activator. Arch Dis Child 1992;67:443-445
42. 42. Kennedy LA, Drummond WH, Knight ME, Millsaps MM, Williams JL. Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator. J Pediatr 1990;116: 798-801
43. 43. Guérin V, Boisseau MR. Efficiency of alteplase in the treatment of venous and arterial thrombosis in the neonate. Am J Hematol 1993;42:236-237
44. 44. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118:467-472
45. 45. Nowak-Göttl U, Schwabe D, Schneider W, Schlösser R, Kreuz W. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992; 340:1105
46. 46. Dillon PW, Fox PS, Berg CJ, Cardella JF, Krummel TM. Recombinant tissue plasminogen activator for neonatal and pediatric vascular thrombolytic therapy. J Pediatr Surg 1983;28:1264-1269
47. 47. Anderson BJ, Keeley SR, Johnson ND. Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator. Anaesthesia and Intensive Care 1991; 19:22-27
48. 48. Berger C, Françoise M, Durand C, Sandre D, Gouyon JB. Utilisation de l'activateur tissulaire du plasminogène (tPA) dans le traitement des thromboses aortiques du nouveau-né. Arch Pediatr 1994;1:1014-1018
49. 49. Doyle E, Britto J, Freeman J, Munro F, Morton NS. Thrombolysis with low dose tissue plasminogen activator. Arch Dis Child 1992;67:1483-1484